Wolfe Research analyst Andrew Rosivach downgrades Innovative Ind Props (NYSE:IIPR) from Outperform to Peer Perform.
NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing
NeuBase Therapeutics Inc (NASDAQ: NBSE) announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program, demonstrating the ability to achieve gene editing with a